Center for Emerging and Re-Emerging Infectious Diseases (CERID)

What Center for Emerging and Re-Emerging Infectious Diseases (CERID) does

CERID is an academic research center within the University of Washington School of Medicine (UW Medicine) that conducts basic and translational research on emerging and re-emerging infectious diseases, including parasitic (malaria, cryptosporidiosis, African Sleeping Sickness, Chagas disease, leishmaniasis), viral (HIV, influenza, herpes, Zika), and bacterial (tuberculosis, cholera) pathogens. The center is headquartered at the UW South Lake Union campus in Seattle and operates specialized infrastructure including BSL-3/ABSL-3 containment, high-throughput flow cytometry under GCLP standards (BD LSRFortessa, five lasers, 18 fluorescent channels) via its Immune Monitoring Core, and large-scale recombinant protein production (up to 36L E. coli expression) via its Recombinant Protein Upscale Center.

Its core technology platform is built around structure-guided drug discovery, with a particular emphasis on bumped kinase inhibitors (BKIs) and other molecular target-based therapeutics developed over more than 25 years by Director Wesley C. Van Voorhis. Supporting capabilities include genomic libraries and genome-spanning ORF sets for interrogating CD8 and CD4 T-cell responses to large-genome pathogens, plus shared laboratory equipment (real-time PCR, plate readers, spectrophotometers) available to UW researchers. The center also hosts the United World for Antiviral Research Network (UWARN), a collaborative research program with international partner laboratories in Brazil, Pakistan, Senegal, South Africa, and Taiwan, supported by a dedicated UWARN Data Management Portal.

CERID operates as a non-profit academic research organization rather than a commercial entity. Revenue is sourced from NIH/NIAID federal grants (notably an $8.75M CREID award over 5 years), foundation grants from the Bill and Melinda Gates Foundation and The Rockefeller Foundation, a $501K C-Path Translational Therapeutics Accelerator Grant, charitable donations through UW's giving program, and internal recharge-center fees from its shared laboratory services. Its customer base consists of academic and medical researchers, graduate students and postdoctoral fellows, international partner institutions in the CREID network, and Seattle-area healthcare providers (University of Washington Medical Center, Harborview Medical Center, Seattle Children's Hospital).

Name

Center for Emerging and Re-Emerging Infectious Diseases (CERID)

Legal name

Center for Emerging and Re-Emerging Infectious Diseases

Website

https://cerid.uw.edu

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

The Center for Emerging and Re-Emerging Infectious Diseases (CERID) is a non-profit academic research center at the University of Washington conducting structure-guided drug discovery, immunology, genomics, and diagnostics research on parasitic, viral, and bacterial pathogens, and coordinating the UWARN global antiviral research network across 30+ countries.

Ownership category

akta.pro rank

Product category

Infectious Disease Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC)

akta.pro secondary industries

Disease-Specific Reference Laboratory Networks (e.g., TB, HIV, Influenza) (HLAJAIAD), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF), General Infectious Disease (HLAKAGAA)

Keywords

• Infectious disease research
• Structure-guided drug discovery
• Antiviral research network
• Vaccine immunology research
• Pathogen genomic surveillance

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. NIH and Government Grants: Primary funding from National Institutes of Health (NIH), including NIAID grants such as the UWARN CREID grant ($8.75M over 5 years), and other federal research funding
2. Foundation and Grant Funding: Funding from foundations including Bill and Melinda Gates Foundation, The Rockefeller Foundation, and other research foundations supporting global health research
3. Donations and Charitable Giving: The center accepts charitable donations through the University of Washington giving program to fund new studies, equipment and experts

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

CERID is a University of Washington academic research center conducting basic and translational research on emerging and re-emerging infectious diseases including parasitic, bacterial, and viral pathogens. It provides shared laboratory infrastructure and services (recombinant protein production, immune monitoring flow cytometry, shared equipment), runs the UWARN international antiviral research network, and conducts structure-guided drug discovery with over 25 years of experience targeting malaria, cryptosporidiosis, and other parasitic diseases.

Product overview

CERID is an academic research center at the University of Washington, not a commercial product company. It operates as a unified research organization offering shared laboratory services and research programs rather than a platform-plus-modules architecture. Its core offerings include the Recombinant Protein Upscale Center (RPUC) for protein production, the CERID Immune Monitoring Core (CIMC) for flow cytometry services, shared equipment access, and undergraduate research opportunities. CERID also hosts the UWARN research program, a global collaborative network focused on emerging viral infectious diseases with an associated data management portal.

Differentiator

Problem solved

Functional benefit

Brands

• UWARN (United World for Antiviral Research Network): A collaborative research network addressing emerging viral infectious diseases with partner laboratories in Brazil, Pakistan, Senegal, South Africa, and Taiwan

Products and services

• Recombinant Protein Upscale Center (RPUC) A recharge center assisting researchers with large-scale recombinant protein production and purification using E. coli expression systems, including IMAC and SEC purification services, with up to 36L capacity. Available to UW-affiliated researchers and the broader research community.
• CERID Immune Monitoring Core (CIMC) A recharge center providing high-quality flow cytometry services using a BD LSRFortessa configured with five lasers and 18 fluorescent channels, operating under Good Clinical Laboratory Practices (GCLP) standards for clinical sample analysis.
• Shared Equipment Shared laboratory equipment available to CERID researchers including real-time PCR systems, plate readers, spectrophotometers, and other instrumentation supporting infectious disease research workflows.
• Undergraduate Research Opportunities Undergraduate research positions providing hands-on experience in lab safety, high-throughput cloning, tissue culture, and biochemical assays for University of Washington students.
• UWARN (United World for Antiviral Research Network) A collaborative research network addressing emerging viral infectious diseases through surveillance, diagnostics, and therapeutics development with international partner laboratories in Brazil, Pakistan, Senegal, South Africa, and Taiwan.
• UWARN Data Management Portal A web-based portal for managing and analyzing research data from the UWARN collaborative network across international partner institutions.

Quantifiable outcome

• Research addressing diseases that sicken or kill over 200 million people annually
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core and flagship.

• Rockefeller UniversitycoreStrategic or Co-development Partner · 1 January 2020UWARN partner collaborating on antiviral research network with investigators from Rockefeller University in New York City working on innovative diagnostic reagents and therapeutic development
• FIOCRUZ (Oswaldo Cruz Foundation)coreStrategic or Co-development Partner · 1 January 2020International partner in Brazil for UWARN research on emerging viral infectious diseases. Collaborators include Luiz Carlos Jr. Alcantara at Oswaldo Cruz Institute in Rio de Janeiro and Isadora Cristina de Siqueira at Instituto Goncalo Moniz in Salvador
• IRESSEF (Institute for Health Research, Epidemiological Surveillance and Training)coreStrategic or Co-development Partner · 1 January 2020International partner in Senegal hosting bioinformatics workshops and supporting research capacity building. Led by Badara Cisse MD MSc PhD, IRESSEF is a key collaborator in West African research initiatives
• KRISP (KwaZulu-Natal Research Innovation and Sequencing Platform)coreStrategic or Co-development Partner · 1 January 2020International partner in South Africa led by Tulio de Oliveira PhD, providing bioinformatics expertise and sequencing capabilities for viral research and pandemic preparedness
• Aga Khan University (Pakistan)coreStrategic or Co-development Partner · 1 January 2020International partner in Pakistan represented by Najeeha Iqbal PhD, contributing to the UWARN network's global research capabilities in South Asia
• Chang Gung University (Taiwan)coreStrategic or Co-development Partner · 1 January 2020International partner in Taiwan led by Shin-Ru Shih PhD at Chang Gung Memorial Hospital and Chang Gung University, contributing research capabilities from the Research Center for Emerging Viral Infections
• Fred Hutchinson Cancer Research CentercoreStrategic or Co-development Partner · 1 January 2020Local Seattle partner contributing to UWARN research with Vaccine and Infectious Disease Division expertise. Paul Edlefsen PhD serves as Co-Investigator
• Institute for Protein DesigncoreTechnology or Integration · 1 January 2020UW-affiliated institute providing expertise in designed protein nanoparticle vaccines and LOCKR technology for developing innovative diagnostic reagents including viral-neutralizing antibodies
• CREID Coordination Center (RTI International and Duke University)flagshipStrategic or Co-development Partner · 1 January 2020The CREID Coordination Center is led by Research Triangle Institute (RTI) and Duke University (including Duke Human Vaccine Institute) to coordinate the global CREID Network of 10 NIAID Centers
• Seattle Structural Genomics Center for Infectious Disease (SSGCID)coreStrategic or Co-development PartnerCERID houses a portion of SSGCID's protein production pipeline. SSGCID accepts requests for protein expression and structure determination in infectious disease organisms and provides recombinant materials free of charge
• Center for Innate Immunity and Immune Disease (CIIID)coreStrategic or Co-development PartnerAffiliated UW center focused on innate immunity research, directed by Michael Gale Jr. PhD who serves as Co-Director of CERID
• Center for One Health Research (COHR)coreStrategic or Co-development PartnerAffiliated UW center directed by Peter Rabinowitz MD MPH who serves as Co-Director of the Alliance for Pandemic Preparedness and is a Co-Director of CERID
• Alliance for Pandemic PreparednesscoreStrategic or Co-development PartnerCollaborative initiative co-directed by Peter Rabinowitz with CERID investigators, providing surveillance for emerging pandemic viruses and expanding understanding of viral immune responses

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Others

• Seattle Children's Research Institute: Pediatric research institute collaborating with CERID on infectious disease research and operating adjacent immunology and global health programs; an ecosystem participant rather than a direct competitor.
• Wellcome Sanger Institute: UK-based genomic sequencing and surveillance powerhouse with overlapping pathogen genomics and outbreak response capabilities; a reference partner for genomic epidemiology rather than a direct competitor.
• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership funding vaccine development against epidemic threats; not a research lab itself but a key funder/convener in the same pandemic preparedness and emerging infectious disease ecosystem as CERID.

Broad incumbents

• NIAID Rocky Mountain Laboratories: NIAID's flagship BSL-equipped intramural laboratory conducting high-containment research on viral and bacterial pathogenesis; broader scope and federal scale but a directly analogous infectious disease research mission.
• Institut Pasteur: Internationally renowned French non-profit research institute covering infectious disease surveillance, immunology, and structure-guided research; far larger scale but overlapping mission in emerging infectious disease preparedness.

Direct peers

• Fred Hutchinson Cancer Center: Seattle-based non-profit research center with a Vaccine and Infectious Disease Division; CERID explicitly collaborates with Fred Hutch through the UWARN network, making it the closest peer in infectious disease research scope and geography.
• La Jolla Institute for Immunology: Independent non-profit research institute focused on infectious disease immunology and vaccine development, with comparable academic, non-commercial operating model and similar investigator-driven structure to CERID.
• Trudeau Institute: Non-profit biomedical research institute historically focused on infectious disease immunology; similar academic, non-commercial model with a small faculty focused on pathogenesis and immune responses.
• Texas Biomedical Research Institute: Independent non-profit institute in San Antonio operating BSL-3/4 facilities for infectious disease research; analogous profile to CERID as a standalone infectious disease research organization.

Emerging players

• Institute for Protein Design (University of Washington): UW-affiliated institute that is a formal CERID partner, providing designed protein nanoparticle vaccine and LOCKR technology; complementary rather than competitive, but emerging as a peer in structure-based infectious disease R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xbsky.app/profile/uwdeptmedicine.bsky.social
• YouTubeyoutube.com/user/UWDeptMedicine
• Facebookfacebook.com/UWDeptMedicine
• Instagraminstagram.com/uofwa
• LinkedInlinkedin.com/company/cerid-uw

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Center for Emerging and Re-Emerging Infectious Diseases (CERID)